Su­per­nus bags ear­ly-stage CNS drug for $15M up­front in re­newed epilep­sy R&D ef­forts

A few years in­to mar­ket­ing their two epilep­sy drugs, the neu­rol­o­gy and psy­chi­a­try ex­perts at Su­per­nus Phar­ma are go­ing back to the draw­ing board with a new as­set.

Su­per­nus $SUPN is pay­ing $15 mil­lion up­front to ac­quire Bis­cayne Neu­rother­a­peu­tics and their Phase I pro­gram, with de­vel­op­ment and sales mile­stones to­talling $73 mil­lion and $95 mil­lion re­spec­tive­ly. A low sin­gle dig­it roy­al­ty would al­so be due should the drug ever reach the mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.